Navigation Links
Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
Date:7/29/2011

er of 2010.

Product Sales Performance Total product sales increased 8 percent to $3,893 million in the second quarter of 2011 versus $3,613 million in the second quarter of 2010.  U.S. product sales increased 7 percent to $2,975 million in the second quarter of 2011 versus $2,787 million in the second quarter of 2010.  International sales increased 11 percent to $918 million in the second quarter of 2011 versus $826 million in the second quarter of 2010.  Excluding the $34 million favorable impact of foreign exchange in the second quarter of 2011, both total product sales and international product sales increased 7 percent.

Aranesp® (darbepoetin alfa) sales decreased 3 percent to $585 million in the second quarter of 2011 versus $603 million in the second quarter of 2010.  U.S. Aranesp sales decreased 10 percent to $241 million in the second quarter of 2011 versus $267 million in the second quarter of 2010, due principally to a mid-teens percentage point decrease in unit demand, offset partially by an increase in the average net sales price.  This sales decrease reflects an overall decline in the segment.  International Aranesp sales increased 2 percent to $344 million in the second quarter of 2011 versus $336 million in the second quarter of 2010.  Excluding the $10 million favorable impact of foreign exchange in the second quarter of 2011, international Aranesp sales decreased 1 percent due principally to a low single-digit percentage point decrease in the average net sales price, substantially offset by an increase in unit demand.  This sales decrease reflects an overall decline in the segment, largely offset by an increase in share and expansion into newer territories. 

EPOGEN® (Epoetin alfa) sales decreased 17 percent to $543 million in the second quarter of 2011 versus $657 million in the second quarter of 2010, due primarily to a decline in unit demand. The decrease in unit demand
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
2. Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
3. Amgen’s First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... and MARSEILLE, France , July 24, ... global license from University of Tokyo enables development of ... gene panels, for blood cancers  Mutations of ... favorable prognosis for patients with bone marrow disorders known ... developing companion diagnostics to guide treatment with new anti-cancer ...
(Date:7/24/2014)... 2014  IRIDEX Corporation (NASDAQ: IRIX ) ... 2014 financial results after the market closes on ... release, the Company will host a conference call with ... on Thursday, July 31, 2014 to ... developments. Interested parties may access the live ...
(Date:7/24/2014)... 24, 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a ... announced its financial results for the second quarter ended June ... , Total revenues of $6.5 million in the second quarter ... in 2013 , Total revenues of $13.3 million for ... 78% over the same period in 2013 , Total ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... Sept. 12, 2011 The National Association of ... that facilitates cooperation between law enforcement, healthcare professionals, ... prevention and investigation of drug diversion – today ... survey by the Substance Abuse and Mental Health ...
... HAYWARD, Calif., Sept. 12, 2011 Intarcia Therapeutics, ... abstracts on ITCA 650 (DUROS® subcutaneous continuous delivery ... diabetes at the 47th Annual Meeting of the ... Lisbon, Portugal.  All three presentations are scheduled for ...
Cached Medicine Technology:Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 2Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 3Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 4
(Date:7/25/2014)... Ireland (PRWEB) July 26, 2014 ... quality legal help to people who have suffered ... the launch of both their new company, and ... article on the new website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims ... law. The focus of the company is always ...
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 In recent ... about, and eager to reverse the symptoms associated with age-related ... the media at large, a new case study ... real benefits of testosterone therapy using bioidentical hormones. , ... 38-year-old father from Seattle who found himself beginning to feel ...
(Date:7/25/2014)... 2014 A federal judge has denied ... DePuy Pinnacle hip lawsuits ( http://www.depuypinnacle-lawsuit.com/ ) selected ... to go before a jury on September 1, 2014, ... July 18th, U.S. District Judge Ed Kinkeade of the ... claims may proceed to trial against Johnson & Johnson, ...
(Date:7/25/2014)... York, NY (PRWEB) July 25, 2014 ... ticket prices across the board for the Guinness International ... FC and Olympiacos FC at Soldier Field on ... also offering their customer appreciation promo/coupon/offer code SOCCER-2014 for ... an amazing year for diehard soccer fans in North ...
(Date:7/25/2014)... of America (GSA) the nation,s largest ... has chosen Heather M. Young, PhD, RN, ... the 2014 recipient of the Doris Schwartz Gerontological ... by GSA,s Health Sciences Section, is given to ... outstanding and sustained contribution to gerontological nursing research. ...
Breaking Medicine News(10 mins):Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4Health News:Liverpool FC vs. Olympiacos FC Tickets Soldier Field: Ticket Down Slashes Ticket Prices for Guinness International Champions Cup in Chicago on Sunday, July 27th 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2
... HealthDay Reporter , WEDNESDAY, Oct. 5 (HealthDay ... early stage ,breast cancer using Herceptin and chemotherapy, while ... drug known as an anthracycline, improves survival while posing ... tested three different regimens, one of which did not ...
... CHAPEL HILL, N.C. -- Cam Patterson, MD, MBA, division ... at Chapel Hill School of Medicine has been named ... Association Judah Folkman Award in Vascular Biology. The ... at mid-career (within fifteen years of their first faculty ...
... HealthDay Reporter , WEDNESDAY, Oct. 5 (HealthDay ... can safely undergo MRIs to screen for cancer and ... a new study finds. Those procedures include only ... or later or defibrillators manufactured in 2000 or later, ...
... By Jenifer Goodwin HealthDay Reporter , WEDNESDAY, ... mice whose symptoms closely mimic autism in humans. ... the mice in this study come closer to mirroring ... in humans, said senior study author Matthew Anderson, an ...
... WEDNESDAY, Oct. 5 (HealthDay News) -- A new oral drug ... rates and disability progression, according to the results of a ... one of the few oral drugs that treat this type ... for many MS patients, researchers said. "Basically, these ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Oct. 5 ... listeria first linked to tainted cantaloupes has risen to 18, ... 20 states, the U.S. Centers for Disease Control and Prevention ... the cantaloupes in question were recalled Sept. 14, more cases ...
Cached Medicine News:Health News:Drug Combo Might Fight Aggressive Breast Cancer More Safely 2Health News:Drug Combo Might Fight Aggressive Breast Cancer More Safely 3Health News:MRI Safe With More Recent Defibrillators, Pacemakers: Study 2Health News:MRI Safe With More Recent Defibrillators, Pacemakers: Study 3Health News:Scientists Engineer Mice That Have Autism 2Health News:Scientists Engineer Mice That Have Autism 3Health News:Experimental MS Drug Shows Promise 2Health News:Experimental MS Drug Shows Promise 3Health News:18 Deaths From Cantaloupe-Linked Listeria Outbreak: CDC 2Health News:18 Deaths From Cantaloupe-Linked Listeria Outbreak: CDC 3
Inquire...
... work area that will help protect your ... irradiate the work area prior to use, ... be amplified. Containment features reduce the chance ... acrylic windows for a clear view, an ...
... x 24in(h). Designed to protect against ... The PCR Workstation irradiates the workspace prior ... airborne contamination by limiting exposure of experimental ... two fluorescent lights, one UV light, 12 ...
... Electropolished stainless steel ... mounts dampen vibration to ... as isolating vibration-producing equipment ... low-profile design allows for ...
Medicine Products: